Advertisement

Pharmaceutisch Weekblad

, Volume 11, Issue 3, pp 87–91 | Cite as

Effect of albumin distribution

A simulation analysis of the effect of altered albumin distribution on the apparent volume of distribution and apparent elimination rate constant of drugs
  • M. Shimoda
  • E. Kokue
  • T. Hayama
  • T. B. Vree
Article

Abstract

The effects of altered albumin distribution on the apparent volume of distribution (V) and the apparent elimination rate constant (k) of drugs were investigated by a simulation analysis. The Equations derived by Øieet al. were modified for this purpose. Within the range observed in normal healthy subjects and patients, the change in albumin distribution significantly affectedV of drugs but, in general, notk. For drugs with more than 90% plasma-protein binding,V changed by more than 100%. The change in plasma-protein binding caused by an altered albumin distribution produced a greater effect onV than that caused by an altered albumin amount. These results suggest that albumin distribution is an important factor in controlling the kinetics of drugs which are highly bound to plasma protein. This is illustrated using midazolam as an example.

Keywords

Albumin Clearance Distribution Midazolam Models, theoretical Pharmacokinetics Protein binding 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Øie S, Tozer TN. Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 1979;68:1203–5.PubMedGoogle Scholar
  2. 2.
    Yacobi A, Levy G. Comparative pharmacokinetics of coumarin anticoagulants. XIV. Relationship between protein binding, distribution, and elimination kinetics of warfarin in rats. J Pharm Sci 1975;64:1660–4.PubMedGoogle Scholar
  3. 3.
    Yacobi A, Lay C-M, Levy G. Comparative pharmacokinetics of coumarin anticoagulants. XXXI. Effect of plasma protein binding on distribution kinetics of dicumarol in rats. J Pharm Sci 1977;66:1741–3.PubMedGoogle Scholar
  4. 4.
    Yacobi A, Levy G. Effect of serum protein binding on sulfisoxazole distribution, metabolism and excretion in rats. J Pharm Sci 1979;68:742–6.PubMedGoogle Scholar
  5. 5.
    Ladefoged O. The influence of protein binding on pharmacokinetics of sulfadimethoxine in rabbit. Acta Pharmacol Toxicol 1978;43:43–50.Google Scholar
  6. 6.
    Meffin PJ, Robert EW, Winkle RA, Harapat S, Peters FA, Harrison DC. Role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokinet Biopharm 1979;7:29–46.PubMedGoogle Scholar
  7. 7.
    Lin JH, Hooke KF, Yeh KC, Duggan DE. Dosedependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism. J Pharmacol Exp Ther 1986;235:402–6.Google Scholar
  8. 8.
    Plantin L-O, Ahlinder S, Norberg R. Birke G. The distribution of proteins between intra- and extracellular spaces in health and disease. Acta Med Scand 1971;189:304–14.Google Scholar
  9. 9.
    Gleichmann WG, Backmann GW, Dengler HJ, Dudeck J. Effect of hormonal contraceptives and pregnancy on serum protein pattern. Eur J Clin Pharmacol 1973;5:218–25.Google Scholar
  10. 10.
    Krüger-Thiemer E, Diller W, Bünger P. Pharmacokinetic models regarding protein binding of drugs. Antimicrob Agents Chemother 1965;5:183–91.Google Scholar
  11. 11.
    Gibaldi M, Levy GL, McNamara PJ. Effect of plasma protein and tissue binding on the biological half-life of drugs. Clin Pharmacol Ther 1978;24:1–4.PubMedGoogle Scholar
  12. 12.
    McNamara PJ, Levy G, Gibaldi M. Effect of plasma protein binding on the time course of drug concentration in plasma. J Pharmacokinet Biopharm 1979;7:195–206.Google Scholar
  13. 13.
    Faed M. Protein binding of drugs in plasma, interstitial fluid and tissues: effect on pharmacokinetics. Eur J Clin Pharmacol 1981;21:77–81.PubMedGoogle Scholar
  14. 14.
    Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981;30:653–61.PubMedGoogle Scholar
  15. 15.
    Dirksen MSC, Vree TB, Driessen JJ. Clinical pharmacokinetics of long-term infusion of midazolam in clinically ill patients. Preliminary results. Anaesth Intens Care 1987;15:440–4.Google Scholar
  16. 16.
    Oldenhof H, De Jong M, Steenhoek A, Janknegt R. Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability. Clin Pharmacol Ther 1988;43:263–9.PubMedGoogle Scholar
  17. 17.
    Jensen JH, Rossing N, Andersen SB, Jarnum S. Albumin metabolism in the nephrotic syndrome in adults. Clin Sci 1967;33:445–57.PubMedGoogle Scholar
  18. 18.
    Jusko WJ, Gretch M. Plasma and tissue binding of drugs in pharmacokinetics. Drug Metab Rev 1976;5:43–140.Google Scholar
  19. 19.
    Tillement J-P, Lhoste F, Ciudielli JF. Disease and drug protein binding. Clin Pharmacokinet 1978;3:144–54.PubMedGoogle Scholar
  20. 20.
    Vree TB, Martea M, Tiggeler RGWL, Hekster YA, Hafkenscheid JCM. Pharmacokinetics of theophylline and its metabolites in a patient undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 1988;15:390–5.PubMedGoogle Scholar
  21. 21.
    Grossman SH, Davis D, Kichell BB, Shand DG, Routledge PA. Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther 1982;31:350–7.PubMedGoogle Scholar
  22. 22.
    Gugler R, Azarnoff DL, Shoeman DW. Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr 1975;53:445–6.PubMedGoogle Scholar
  23. 23.
    Gugler R, Azarnoff DL. Drug protein binding and nephrotic syndrome. Clin Pharmacokinet 1976;1:25–35.PubMedGoogle Scholar
  24. 24.
    Nancarrow C, Mather LE. Pharmacokinetics in renal failure. Anaesth Intens Care 1983;11:350–60.Google Scholar
  25. 25.
    Blaschke TF. Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 1977;2:32–44.PubMedGoogle Scholar
  26. 26.
    Dromgoole SH. The binding capacity of albumin and renal disease. J. Pharmacol Exp Ther 1974;191:318–23.PubMedGoogle Scholar
  27. 27.
    McNamara PJ, Lalka D, Gibaldi M. Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 1981;98:730–40.PubMedGoogle Scholar
  28. 28.
    Wilkinson GR. Plasma and tissue binding consideration in drug disposition. Drug Metab Rev 1983;14:427–65.PubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1989

Authors and Affiliations

  • M. Shimoda
    • 1
  • E. Kokue
    • 2
  • T. Hayama
    • 2
  • T. B. Vree
    • 1
  1. 1.Department of Clinical PharmacySint Radboud HospitalHB Nijmegenthe Netherlands
  2. 2.Department of Veterinary MedicineTokyo University of Agriculture and TechnologyTokyoJapan

Personalised recommendations